Evaluating the advantages and potential drawbacks of shielding as a method for safe RL. Bettina Könighofer is an assistant professor at Graz University of Technology, Graz, Austria. Roderick Bloem ...
Last month, investors' hopes were dashed as Replimune suggested alignment had not yet been reached with the FDA on RP1’s future. Now, the regulator has accepted a refiled application after all.
NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the "Company"), announced that its clinical lead drug NV ...
Results from pritelivir Phase 2 study demonstrate a favorable safety profile and a numerically higher lesion healing rate vs. foscarnetPritelivir Phase 2 results supported FDA Breakthrough Therapy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback